Please login to the form below

Not currently logged in

Sanofi-aventis to acquire US BiPar Sciences

Sanofi-aventis has announced it has agreed to purchase US biopharmaceutical company, BiPar Sciences

Sanofi-aventis has announced it has agreed to purchase US biopharmaceutical company, BiPar Sciences.

California-based BiPar specialises in the development of pioneering treatments for several different cancers through DNA repair using PARP (Poly ADP-Ribose Polymerase) inhibitors. BSI-201 enhances the effects of chemotherapy by preventing cancer cells from repairing their own DNA and therefore leading to the death of cancer cells.

BiPar's lead product candidate, BSI-201, is currently undergoing Phase 2 trials for the treatment of metastatic triple negative breast cancer and ovarian cancer among others.

Christopher A Viehbacher, CEO of sanofi-aventis said: "This acquisition illustrates our strong commitment to oncology to provide patients, physicians and public health stakeholders with breakthrough medicines addressing unmet medical needs".

Under the terms of the agreement, the final price of the deal depends on BSI-201 achieving milestone payments. The price could reach a maximum of $500m.

15th April 2009


Featured jobs

Subscribe to our email news alerts


Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....